Agenda

Date and TimeTitle
Nov 16, 2020 (Eastern)
9:18am - 10:09am
Pharmacogenomics: Considerations for Implementation and Use in Everyday Patient Care

Through this panel, attendees will learn about practical considerations for implementing pharmacogenomics (PGx) in clinical practice and using PGx results to inform prescribing. Expert panelists from across the healthcare ecosystem with experience implementing and leading pharmacogenomics programs will share their experiences and perspectives in what promises to be a fascinating, timely, and useful discussion. Topics will include:
● Patients and situations where PGx testing can improve care
● The value of PGx testing
● Considerations for test selection
● Implementation – challenges and strategies

Nov 16, 2020 (Eastern)
10:20am - 10:45am
Integrating Pharmacogenetics in Community Care: From the Lab to the Point of Care

Pharmacogenetic testing is becoming a preferred standard of care for some conditions. This is particularly true in mental health, cardiovascular disease, and chronic pain conditions. Adverse drug events caused by inappropriate prescribing are among the top 5 causes of death in North America. Pharmacogenetic tests have been shown to reduce harm to patients by guiding health care providers in their prescribing choices.
The challenge which has been long associated with pharmacogenetics is how the results can be easily and efficiently utilized in a clinical consultation AND be combined in a multi-factorial prescribing decision rather than just another variable to be considered in isolation.

In this presentation, Prof. Dawes will discuss how pharmacogenetics can be incorporated seamlessly into the point of care prescribing workflow within a physical or virtual community care environment. GenXys is a leader in medication decision support software with a suite of PGx enabled ‘digital assistants’ for prescribers.

Nov 16, 2020 (Eastern)
10:50am - 11:40am
The Next CDx Frontier: Developing Targeted Therapies for Complex Neurological Diseases

Companion diagnostics (CDx) have the extraordinary power to connect a patient’s unique genetic profile to a promising, personalized treatment option. While dramatic improvements in outcomes for cancer patients have been observed through this approach, it has yet to take hold in other disease areas, such as those involving the central nervous system.

Neurodegenerative and neurodevelopmental diseases are associated with complex and often repetitive genomic sequences, presenting a challenging testing hurdle for laboratories. Recent advances offer new hope for rare and complex genetic disease treatment. This panel discussion will examine how a biomarker-driven, diagnostics-enabled approach can facilitate the clinical, regulatory, and commercial success of drugs developed in these disease areas.

Nov 16, 2020 (Eastern)
11:40am - 12:31pm
The Business Case For Investing in Precision Health For Your Population

Precision public health focuses on populations and uses genetic testing to assess presumably healthy people without identified personal or family history of heritable disease or suboptimal response to drugs. The goals include early identification of health risks and modification of preventive care approaches, as well as safer and more effective medication use. Panelists will share their experiences implementing precision public health from the perspectives of a large self-insured employer, a health system and a retirement system. These organizations have focused on returning medically actionable results that impact both disease and medication management. We will discuss the barriers and facilitators to implementation, as well as evidence of program impact. The conversation is intended to help decision-makers evaluate the business case for supporting genetic testing in groups such as employees, retirees and members of health systems.

Nov 16, 2020 (Eastern)
12:45pm - 1:20pm
Keynote: Understanding the True Impact of PGx in Healthcare

Systems implementing precision medicine programs have warned that EHR-integrated clinical decision support tools (CDST) must be a priority. See the added value pharmacogenomics and YouScript CDST have provided in impacting clinical decisions and reducing ED visits, hospitalizations, readmissions, and costs. In addition to peer-reviewed studies, we will cover recent real-world validations. These include a Highmark BCBS VITAL innovation program at an Allegheny Health Network clinic and a large-scale longitudinal claims analysis completed by a major U.S. payer.

Nov 16, 2020 (Eastern)
1:25pm - 1:55pm
COVID‑19 and Pharmacogenomics: an Association That Warrants Comprehensive Assessment
Nov 16, 2020 (Eastern)
2:00pm - 3:12pm
STRIPE: A Collaborative Community for Pharmacogenomics

A new pharmacogenomics collaborative community called Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) aims to bring stakeholders together to accelerate the development of personalized medicine practices as a standard of care. The stakeholders in the pharmacogenetics testing space are diverse. They include genetics researchers, consortiums and working groups synthesizing and harmonizing the knowledge base, academic and commercial labs offering genetic tests to help guide physician prescribing, as well as clinicians, patient advocates, genetic counselors, pharmacists, software and analytics providers, insurers, and government entities.

Join members of the STRIPE community as they navigate challenges and pursue opportunities to advance pharmacogenomics through a multi-stakeholder public-private collaborative approach.

Nov 17, 2020 (Eastern)
8:00am - 8:30am
Introduction to Precision Medicine: What is Precision Medicine?

 

 

Nov 17, 2020 (Eastern)
8:30am - 9:05am
Economic Issues in Precision Medicine
Nov 17, 2020 (Eastern)
9:05am - 9:36am
Precision Medicine: The Triple Helix Approach

 

 

Nov 17, 2020 (Eastern)
10:30am - 11:02am
Q & A Session 1

 

 

Nov 17, 2020 (Eastern)
10:30am - 11:02am
Predictive Analytics in PM: Intro to Machine Learning

 

 

Nov 17, 2020 (Eastern)
11:02am - 11:39am
RNA-regulation of Inflammation

 

 

 

Nov 17, 2020 (Eastern)
11:39am - 12:05pm
Cancer Imaging & Treatment Response Assessment: Radiomics, Radiogenomics, and the Role of AI

This event will be viewed under a different URL. 

www.engagez.net/pmls-pharmacogenomicscme

 

Nov 17, 2020 (Eastern)
11:39am - 12:05pm
Q & A Session 2

 

 

Nov 17, 2020 (Eastern)
12:05pm - 12:33pm
Implementation Science of Precision Medicine: Strategies for Optimizing Adoption and Program Evaluation

This event will be viewed under a different URL. 

www.engagez.net/pmls-pharmacogenomicscme

 

Nov 17, 2020 (Eastern)
1:30pm - 1:50pm
Implementation of Pharmacogenetics in Clinical Care

This event will be viewed under a different URL. 

www.engagez.net/pmls-pharmacogenomicscme

 

Nov 17, 2020 (Eastern)
1:50pm - 2:30pm
Clinical Trials in Precision Medicine: Focus in Oncology
Nov 17, 2020 (Eastern)
2:30pm - 3:00pm
Building a Pharmacogenomics Program in a Community-Academic Hybrid Cancer Hospital: From Translational to Clinical Science

 

 

Nov 17, 2020 (Eastern)
2:30pm - 3:00pm
Q & A Session 3